About Nps Pharmaceuticals
NPS Pharmaceuticals is developing specialty therapeutics for gastrointestinal and endocrine disorders. The company is currently advancing two late-stage programs: GATTEX (teduglutide) is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome and in preclinical development for the GI Mucositis and Necrotizing Enterocolitis indications and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism. NPS complements its internal programs with strategic partnerships, which include Amgen, GlaxoSmithKline, Kirin, and Nycomed.n
Nps Pharmaceuticals Patents
Nps Pharmaceuticals has filed 70 patents.
Quantum field theory, Graphene, Nanomaterials, Monolayers, Industrial gases
Quantum field theory, Graphene, Nanomaterials, Monolayers, Industrial gases
Latest Nps Pharmaceuticals News
Sep 16, 2021
May 27, 2014 08:30 AM Eastern Daylight Time BEDMINSTER, N.J.--( BUSINESS WIRE )--NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that senior management, company directors and employees, will ring the NASDAQ Stock Market Opening Bell on Tuesday, May 27, 2014. The ceremony commemorates NPS Pharma’s 20th anniversary of its initial public offering and listing on the NASDAQ. “We have certainly come a long way in the past 20 years, since completing our IPO of 2 million shares at $5.50 per share,” said Francois Nader, MD, president and chief executive officer of NPS Pharma. “Today, NPS Pharma is a thriving global biopharmaceutical company dedicated to patients with rare diseases, who have significant unmet medical needs. With our unwavering commitment to patients at the core of NPS Pharma, we aspire to become the world’s premier rare disease company.” A live webcast of the NASDAQ Opening Bell Ceremony (starting at 9:15 AM Eastern Time on May 27) will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx . About NPS Pharma NPS Pharma is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases. The company’s lead product, Gattex® (teduglutide [rDNA origin]) for injection is approved in the US for adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support. In the EU, teduglutide (trade name: Revestive®) is approved for the treatment of adult patients with SBS; patients should be stable following a period of intestinal adaptation after surgery. Teduglutide is not approved for the treatment of pediatric SBS patients. The safety and efficacy of teduglutide in this population is currently being evaluated in a global trial. A Biologics License Application is undergoing FDA review for Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone. The Prescription Drug User Fee Act goal date for the Natpara application is October 24, 2014. NPS Pharma’s earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium sensing receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS Pharma complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin. Additional information about NPS Pharma is available through its corporate website, http://www.npsp.com . “NPS,” “NPS Pharma,” “NPS Pharmaceuticals,” “Gattex,” “Natpara,” “Natpar,” “Preotact,” and “Revestive” are the company's trademarks. Disclosure notice Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on the company's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward looking statements include, but are not limited to, statements concerning the company’s future financial performance and plans for the commercialization of its products, beliefs or expectations regarding our products in development, statements concerning the company’s plans for international expansion, beliefs or expectations regarding potential revenue and earnings from product sales, including beliefs regarding our ability to grow sales, expectations regarding the market size for our products, including those in development, and beliefs or expectations regarding our operating expenses. Risks associated to the company's business include, but are not limited to, the risks associated with any failure by the company to successfully commercialize Gattex/Revestive (teduglutide [rDNA origin]) for injection, including the risk that physicians and patients may not see the advantages of Gattex/Revestive and may therefore be reluctant to utilize the product, the risk that private and public payers may be reluctant to cover or provide reimbursement for Gattex, risks related to regulatory approvals for recombinant human parathyroid hormone 1-84 (rhPTH [1-84]), the risks associated with the company's strategy, global macroeconomic conditions, the impact of changes in management or staff levels, the effect of legislation effecting healthcare reform in the United States, as well as other risk factors described in the company's periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Form 10-Qs. All information in this press release is as of the date of this press release and NPS undertakes no duty to update this information, whether as a result of new information, future events or otherwise. Contacts
Nps Pharmaceuticals Frequently Asked Questions (FAQ)
When was Nps Pharmaceuticals founded?
Nps Pharmaceuticals was founded in 1986.
Where is Nps Pharmaceuticals's headquarters?
Nps Pharmaceuticals's headquarters is located at 550 Hills Drive, Bedminster.
What is Nps Pharmaceuticals's latest funding round?
Nps Pharmaceuticals's latest funding round is Acq - P2P.
Who are the investors of Nps Pharmaceuticals?
Investors of Nps Pharmaceuticals include Shire, Invesco Private Capital, Weintraub Capital Management, Front Street Capital, MCP Global and 18 more.
Who are Nps Pharmaceuticals's competitors?
Competitors of Nps Pharmaceuticals include Immunomic Therapeutics, Ambrx, Viracta, Adastra Pharmaceuticals, Crown Bioscience and 7 more.
Compare Nps Pharmaceuticals to Competitors
Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.
Embera NeuroTherapeutics is a clinical stage pharmaceutical company developing treatments for to potentially treat a range of addictions located in the greater Boston, MA area.
Neurelis is a specialty pharmaceutical company that devleops and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.
Meditrina Pharmaceuticals is a pharmaceutical company. It focuses on developing and commercializing therapies that treat women's reproductive system disorders. It focuses on gynecologic and aromatase-mediated conditions with serious unmet medical needs. It was founded in 2006 and is based in Ann Arbor, Michigan.
Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the healthcare community with relevant products and services that directly benefit those affected by neurological disorders. In the first half of 2010, Nautilus intends to launch a novel product, CAMBIA¯¿½ (diclofenac potassium for oral solution).
Harkness Pharmaceuticals is focused on developing anti-obesity therapeutics. Per the company, currently more than 20% of the U.S. population are considered clinically obese yet there remain few therapeutic option available. Harkness is performing exploratory human clinical trials in collaboration with the Pennington Institute in Louisiana.